Considerations for Drug Trials in Hypertrophic Cardiomyopathy
- DOI
- 10.1002/ehf2.15138
- Published
- 2024-10-27
- Container
- ESC Heart Failure
- Publisher
- Oxford University Press (OUP)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/ehf2.15138,
title = {Considerations for Drug Trials in Hypertrophic Cardiomyopathy},
author = {John P. Farrant and Matthias Schmitt and Anna B. Reid and Clifford J. Garratt and William G. Newman and Aneil Malhotra and Rhys Beynon and Masliza Mahmod and Betty Raman and Robert M. Cooper and Dana Dawson and Thomas Green and Sanjay K. Prasad and Anvesha Singh and Susanna Dodd and Hugh Watkins and Stefan Neubauer and Christopher A. Miller},
year = {2024},
journal = {ESC Heart Failure},
doi = {10.1002/ehf2.15138},
url = {https://doi.org/10.1002/ehf2.15138}
}RIS
TY - JOUR TI - Considerations for Drug Trials in Hypertrophic Cardiomyopathy AU - John P. Farrant AU - Matthias Schmitt AU - Anna B. Reid AU - Clifford J. Garratt AU - William G. Newman AU - Aneil Malhotra AU - Rhys Beynon AU - Masliza Mahmod AU - Betty Raman AU - Robert M. Cooper AU - Dana Dawson AU - Thomas Green AU - Sanjay K. Prasad AU - Anvesha Singh AU - Susanna Dodd AU - Hugh Watkins AU - Stefan Neubauer AU - Christopher A. Miller PY - 2024 JO - ESC Heart Failure DO - 10.1002/ehf2.15138 UR - https://doi.org/10.1002/ehf2.15138 ER -
APA
Farrant, J. P., Schmitt, M., Reid, A. B., Garratt, C. J., Newman, W. G., Malhotra, A., Beynon, R., Mahmod, M., Raman, B., Cooper, R. M., Dawson, D., Green, T., Prasad, S. K., Singh, A., Dodd, S., Watkins, H., Neubauer, S., & Miller, C. A. (2024). Considerations for Drug Trials in Hypertrophic Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.15138
Source records
- crossref · retrieved 2026-09-26T21:39:49.316Z